IP Library Granted Patent US 7,807,456
Granted Patent B2
US 7,807,456 · App. 12/640,645 · Granted Oct 5, 2010

Recombinant attenuated

Assignee: Intervet Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,456
App. No.
12/640,645
Granted
Oct 5, 2010
Kind
B2
Abstract

The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His 68 . The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.

Claims (24)

1. A recombinant nucleic acid molecule that encodes a substantially nontoxic mutein of Clostridium perfringens alpha-toxin; wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 9 consecutive amino acid residues, with no more than 48 consecutive amino acid residues deleted; and wherein one of the deleted amino acid residues is His 68 .

2. The recombinant nucleic acid molecule of claim 1 wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 12 consecutive amino acid residues; and wherein one of the deleted amino acid residues is His 68 .

3. The recombinant nucleic acid molecule of claim 2 wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 18 consecutive amino acid residues; and wherein one of the deleted amino acid residues is His 68 .

4. The recombinant nucleic acid molecule of claim 1 wherein the mutein alpha-toxin comprises SEQ ID NO: 3 minus 9 consecutive amino acid residues ranging from Tyr 62 through Trp 70 .

5. The recombinant nucleic acid molecule of claim 1 comprising the nucleic acid sequence of SEQ ID NO: 2; wherein nucleotides 268-294 of the nucleic acid molecule are deleted.

6. The recombinant nucleic acid molecule of claim 5 wherein the deleted nucleotides are replaced by a nucleotide sequence encoding a single Leu residue.

7. A recombinant nucleic acid molecule that encodes a substantially nontoxic mutein of Clostridium perfringens alpha-toxin;

wherein the substantially nontoxic mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 in which His 68 is deleted together with an additional 4 to 60 flanking amino acid residues; and

wherein the attenuated Clostridium perfringens organism is substantially nontoxic due to a lack of a functional wild-type plc gene.

8. The recombinant nucleic acid molecule of claim 1 wherein the substantially nontoxic mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 with no more than 36 consecutive amino acid residues deleted.

9. The recombinant nucleic acid molecule of claim 8 wherein the substantially nontoxic mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 with no more than 24 consecutive amino acid residues deleted.

10. The recombinant nucleic acid molecule of claim 9 wherein the substantially nontoxic mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 with no more than 18 consecutive amino acid residues deleted.

11. A vector that expresses a recombinant nucleic acid molecule that encodes a substantially nontoxic mutein of Clostridium perfringens alpha-toxin; wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 9 consecutive amino acid residues, with no more than 48 consecutive amino acid residues deleted; and wherein one of the deleted amino acid residues is His 68 .

12. The vector of claim 11 wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 12 consecutive amino acid residues; and wherein one of the deleted amino acid residues is His 68 .

13. The vector of claim 12 wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 18 consecutive amino acid residues; and wherein one of the deleted amino acid residues is His 68 .

14. The vector of claim 11 wherein the mutein alpha-toxin comprises SEQ ID NO: 3 minus 9 consecutive amino acid residues ranging from Tyr 62 through Trp 70 .

15. The vector of claim 11 comprising the nucleic acid sequence of SEQ ID NO: 2; wherein nucleotides 268-294 of the nucleic acid molecule are deleted.

16. The vector of claim 15 wherein the deleted nucleotides are replaced by a nucleotide sequence encoding a single Leu residue.

17. A vector that expresses a recombinant nucleic acid molecule that encodes a substantially nontoxic mutein of Clostridium perfringens alpha-toxin;

wherein the substantially nontoxic mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 in which His 68 is deleted together with an additional 4 to 60 flanking amino acid residues; and

wherein the attenuated Clostridium perfringens organism is substantially nontoxic due to a lack of a functional wild-type plc gene.

18. The vector of claim 11 wherein the substantially nontoxic mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 with no more than 36 consecutive amino acid residues deleted.

19. The vector of claim 18 wherein the substantially nontoxic mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 with no more than 24 consecutive amino acid residues deleted.

20. The vector of claim 19 wherein the substantially nontoxic mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 with no more than 18 consecutive amino acid residues deleted.

Assignments (1)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
Continuity (3)
Division 1173445400 · Apr 12, 2007
Provisional Application 6079255300 · Apr 17, 2006
Related Publication 20100166800A1 · Jul 1, 2010